Literature DB >> 21931475

The value of branded proton pump inhibitors: formulary considerations.

David A Peura, Rosemary R Berardi, Javier Gonzalez, Louis Brunetti.   

Abstract

The prevalence of gastroesophageal reflux disease (GERD) continues to rise, placing an increasing burden on our health care system. Proton pump inhibitors (PPIs) are the most effective and widely used therapy for GERD. Many PPIs are now available in generic and over-the-counter forms, and managed care formularies often choose these as their preferred drug for GERD treatment. However, newer-generation branded PPIs, as a result of differences in their pharmacokinetic and pharmacodynamic profiles, may offer clinical advantages over generic PPIs. This article discusses these differences and the advantages they offer and suggests possible ways to incorporate the newer PPIs into formularies.

Entities:  

Year:  2011        PMID: 21931475      PMCID: PMC3171810     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  59 in total

1.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey.

Authors:  William D Chey; John M Inadomi; Anna M Booher; Virender K Sharma; A Mark Fendrick; Colin W Howden
Journal:  Am J Gastroenterol       Date:  2005-06       Impact factor: 10.864

3.  The burden of selected digestive diseases in the United States.

Authors:  Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

Review 4.  Review article: the opportunities and benefits of extended acid suppression.

Authors:  C Scarpignato; I Pelosini
Journal:  Aliment Pharmacol Ther       Date:  2006-06       Impact factor: 8.171

5.  Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population.

Authors:  Thomas Delate; Douglas E Mager; Jagat Sheth; Brenda R Motheral
Journal:  Am J Manag Care       Date:  2005-01       Impact factor: 2.229

6.  Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.

Authors:  Majid Vakily; Weijiang Zhang; Jingtao Wu; Stuart N Atkinson; Darcy Mulford
Journal:  Curr Med Res Opin       Date:  2009-03       Impact factor: 2.580

7.  Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.

Authors:  R Fass; W D Chey; S F Zakko; N Andhivarothai; R N Palmer; M C Perez; S N Atkinson
Journal:  Aliment Pharmacol Ther       Date:  2009-04-08       Impact factor: 8.171

8.  Cardiovascular outcomes after a change in prescription policy for clopidogrel.

Authors:  Cynthia A Jackevicius; Jack V Tu; Virginie Demers; Magda Melo; Jafna Cox; Stephane Rinfret; Dimitri Kalavrouziotis; Helen Johansen; Hassan Behlouli; Alice Newman; Louise Pilote
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

9.  Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort.

Authors:  P Wahlqvist; M Karlsson; D Johnson; J Carlsson; S C Bolge; M-A Wallander
Journal:  Aliment Pharmacol Ther       Date:  2008-02-29       Impact factor: 8.171

10.  GERD-related health care utilization, therapy, and reasons for transfer of GERD patients between primary care providers and gastroenterologists in a US managed care setting.

Authors:  Rachel Halpern; Smita Kothari; Mahesh Fuldeore; Victoria Zarotsky; Victoria Porter; Omar Dabbous; Jay L Goldstein
Journal:  Dig Dis Sci       Date:  2009-08-21       Impact factor: 3.199

View more
  3 in total

1.  Proton pump inhibitors and vascular function: A prospective cross-over pilot study.

Authors:  Yohannes T Ghebremariam; John P Cooke; Fouzia Khan; Rahul N Thakker; Peter Chang; Nigam H Shah; Kevin T Nead; Nicholas J Leeper
Journal:  Vasc Med       Date:  2015-04-02       Impact factor: 3.239

2.  Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.

Authors:  Xiao-Ping Niu; Bao-Ping Yu; Yun-Dong Wang; Zhen Han; Shao-Fen Liu; Chi-Yi He; Guo-Zheng Zhang; Wan-Chun Wu
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

3.  Profile of the Change in Depression during Proton-Pump Inhibitor Therapy in Patients with Gastroesophageal Reflux Disease: Influence of the Mucosal Break.

Authors:  Chia-Liang Wu; Chien-Lin Chen; Shu-Hui Wen
Journal:  Int J Environ Res Public Health       Date:  2021-06-02       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.